Related references
Note: Only part of the references are listed.Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio Omuro et al.
NEURO-ONCOLOGY (2023)
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?
Matthias Preusser et al.
NEURO-ONCOLOGY (2023)
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma A Phase 3 Prospective Externally Controlled Cohort Trial
Linda M. Liau et al.
JAMA ONCOLOGY (2023)
Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
Da Qian et al.
BIOMEDICINE & PHARMACOTHERAPY (2023)
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination
Francesco Pasqualetti et al.
BRITISH JOURNAL OF CANCER (2023)
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
T. Olivier et al.
REVUE NEUROLOGIQUE (2023)
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
Xiaoxia Chi et al.
FRONTIERS IN IMMUNOLOGY (2023)
Advances in dendritic cell vaccination therapy of cancer
Sajad Najafi et al.
BIOMEDICINE & PHARMACOTHERAPY (2023)
External control arms in oncology: current use and future directions
P. S. Mishra-Kalyani et al.
ANNALS OF ONCOLOGY (2022)
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim et al.
NEURO-ONCOLOGY (2022)
Leveraging external data in the design and analysis of clinical trials in neuro-oncology
Rifaquat Rahman et al.
LANCET ONCOLOGY (2021)
Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?
Vinay Prasad
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Michael Platten et al.
NATURE (2021)
The Current Landscape of Immune Checkpoint Blockade in Glioblastoma
Oluwatosin O. Akintola et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
Eudocia Q. Lee et al.
CANCER (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
Fiona A. Desland et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma
Alba A. Brandes et al.
ONCOLOGIST (2019)
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
Evanthia Galanis et al.
CANCER (2019)
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2019)
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson et al.
NATURE IMMUNOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PD-L1/PD-1 Axis in Glioblastoma Multiforme
Jakub Litak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma
Yoshitaka Narita et al.
NEURO-ONCOLOGY (2019)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses
Timothy Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma
M. A. Qazi et al.
ANNALS OF ONCOLOGY (2017)
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
DCVax®-L-Developed by Northwest Biotherapeutics
Stavros Polyzoidis et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2013)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Scale to Predict Survival After Surgery for Recurrent Glioblastoma Multiforme
John K. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells-Significant Roles of CXCL10
Mitsugu Fujita et al.
CANCER RESEARCH (2009)
A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro
Q. Zhou et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice
S. Pellegatta et al.
NEUROLOGICAL RESEARCH (2006)
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
LM Liau et al.
CLINICAL CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer
Bing-Ya Liu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
AB Heimberger et al.
JOURNAL OF NEUROIMMUNOLOGY (2000)
Share Paper
